Mesenchymal precursor cell

To provide an update on the ongoing multi-centre Phase 2 clinical trial of the proprietary mesenchymal precursor cell (MPC) technology in patients with heart attacks, a press conference was held by the doctors at Houston’s Texas Heart Institute last Saturday.

Allogeneic, stem cell therapy

This is the first trial in the world to evaluate an allogeneic, stem cell therapy injected directly into damaged heart muscle by cardiac catheter.The trial’s 25 patients are currently being enrolled at multiple sites in the United States by Mesoblast’s (ASX:MSB; USOTC:MBLTY) sister company, Angioblast Systems Inc. Patients will get either placebo or one of three gradually increasing doses of the proprietary adult stem cells.

Cardiac catheter

It has been counted the first trial in the world to examine an allogeneic stem cell therapy injected directly into damaged heart muscle by cardiac catheter. 25 patients are currently being enrolled at multiple sites in the United States by Mesoblast’s (ASX: MSB; USOTC: MBLTY) sister company, Angioblast Systems Inc for the trial.

(more…)

Chicago- A new resuscitation technique, which involves a round of two hundred chest compressions prior to a defibrillator shock, can increase the survival rate of persons when they experience a cardiac arrest, U.S. researchers reported on Tuesday.

In Arizona, rescue teams who employed the new technique of resuscitation on people who have had a cardiac arrest outside the hospital saw the survival rate triple when compared to that of the standard approach.

“Cardiac arrest is extremely common but the survival rate is very low,” said Dr. Bentley Bobrow, whose study was published in the Journal of the American Medical Association.

The new study was conducted in two cities in Arizona and it included 2,460 persons who had cardiac arrest outside of the hospital. About 1,799 people received treatment before the emergency personnel got trained in the new technique, which is named as minimally interrupted cardiac resuscitation (MIRC).

(more…)